Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Market Chatter: US Appeals Court Overturns $1.2 Billion Verdict Against Gilead Sciences, Invalidates Bristol Myers CAR-T Patent

08/26/2021 | 04:11pm EDT


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
10/22GILEAD SCIENCES : Presents Long-Term Switch Data Reinforcing Biktarvy as a Treatment Optio..
AQ
10/21GILEAD SCIENCES : Presents Long-Term Switch Data Reinforcing Biktarvy« as a Treatment Opti..
BU
10/21Gilead Sciences, Inc. Presents Long-Term Switch Data Reinforcing Biktarvy as A Treatmen..
CI
10/21GILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy for..
AQ
10/20GILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy« fo..
PU
10/19Atea plunges after COVID-19 treatment fails to help patients in study
RE
10/19GILEAD SCIENCES : to Donate 103,000 Vials of Veklury to Indonesia, Armenia
MT
10/19GILEAD SCIENCES : Announces Veklury« Donations to Help Address the Ongoing COVID-19 Crisis..
BU
10/19GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
AQ
10/18GILEAD SCIENCES : Secures FDA Approval for Expanded Indication of Biktarvy for Treatment o..
MT
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 202 M - -
Net income 2021 6 431 M - -
Net Debt 2021 23 041 M - -
P/E ratio 2021 13,4x
Yield 2021 4,17%
Capitalization 84 845 M 84 845 M -
EV / Sales 2021 4,28x
EV / Sales 2022 4,23x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 67,67 $
Average target price 76,35 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992
BEIGENE, LTD.49.95%36 160